Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

BACKGROUND: This study aims to comprehensively summarize the currently available evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced pancreatic cancer. METHODOLOGY/PRINCIPAL FINDINGS: PubMed, EMBASE, The Cochrane Library and abstracts of recent major conferences...

Full description

Bibliographic Details
Main Authors:	Zu-Yao Yang, Jin-Qiu Yuan, Meng-Yang Di, Da-Yong Zheng, Jin-Zhang Chen, Hong Ding, Xin-Yin Wu, Ya-Fang Huang, Chen Mao, Jin-Ling Tang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3589410?pdf=render

Similar Items

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
by: Wang Y, et al.
Published: (2016-06-01)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
by: Reham Abdel-Wahab, et al.
Published: (2018-05-01)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
by: Shuling Chen, et al.
Published: (2023-03-01)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
by: Zhou Zhu, et al.
Published: (2023-10-01)

Erlotinib in the treatment of advanced pancreatic cancer
by: Robin K Kelley, et al.
Published: (2008-03-01)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
by: Zhiyong Liu, et al.
Published: (2022-07-01)

Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib
by: Yin N, et al.
Published: (2020-10-01)

Real-world outcomes of adjuvant gemcitabine gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
by: Sora Kang, et al.
Published: (2022-05-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
by: J L Xu, et al.
Published: (2015-01-01)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
by: Konstantin Schlick, et al.
Published: (2023-08-01)

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
by: Jiayuan Chen, et al.
Published: (2021-07-01)

A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer
by: Jin JIANG, et al.
Published: (2011-01-01)

Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model
by: Ching-Fu Chang, et al.
Published: (2019-01-01)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
by: Ruijian Li, et al.
Published: (2023-08-01)

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
by: Zhan Shi, et al.
Published: (2022-03-01)

[Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis].
by: Brunner, T
Published: (2012)

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
by: Zhang F, et al.
Published: (2022-02-01)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022-07-01)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
by: Jianhui Yang, et al.
Published: (2021-10-01)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
by: Seung Tae Kim, et al.
Published: (2015-02-01)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
by: Haorui Li, et al.
Published: (2023-10-01)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
by: Zhu X, et al.
Published: (2018-10-01)

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report
by: Lincer Robert, et al.
Published: (2010-10-01)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
by: Kazuto Nishio, MD, PhD, et al.
Published: (2021-06-01)

Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
by: Marko Damm, et al.
Published: (2021-08-01)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
by: Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
Published: (2011-01-01)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
by: Ke Wang, et al.
Published: (2022-08-01)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
by: Yunjiang Zhou, et al.
Published: (2019-04-01)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
by: Guo ZY, et al.
Published: (2018-08-01)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
by: Myles A. Ingram, et al.
Published: (2022-09-01)

Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
by: Xi Guo, MD, et al.
Published: (2020-03-01)

Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study
by: Chen Z, et al.
Published: (2023-11-01)

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
by: Wen-Zhao Zhong, et al.
Published: (2023-02-01)

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
by: Tae Hwan Kim, et al.
Published: (2017-09-01)

A Meta-Analysis of Platinum Plus Gemcitabine or Vinorelbine for Advanced Non-small Cell Lung Cancer
by: Guanghui GAO, et al.
Published: (2009-01-01)

GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer
by: Chen Chen, et al.
Published: (2022-07-01)